Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer

Charles Lawrence Loprinzi, Richard M. Goldberg, John Q. Su, James A. Mailliard, Steven A. Kuross, Andrew W. Maksymiuk, John W. Kugler, James R. Jett, Chirantan Ghosh, Delano M. Pfeifle, Donald B. Wender, Patrick A. Burch

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Purpose: Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. Patients and Methods: Patients on this trial had newly diagnosed, unresectable non-small-cell lung cancer and were treated with cisplatin and etoposide. In addition, they were randomized to receive hydrazine sulfate or placebo in a double-blind manner. Results: A total of 243 patients were randomized. Response rates were similar in the two treatment arms. There were trends for worse time to progression and survival in the hydrazine sulfate arm. No significant differences were noted in the two study arms with regard to toxicity or quality of life (QL). Conclusion: This trial failed to demonstrate any benefit for patients who received hydrazine sulfate.

Original languageEnglish (US)
Pages (from-to)1126-1129
Number of pages4
JournalJournal of Clinical Oncology
Volume12
Issue number6
StatePublished - Jun 1994

Fingerprint

hydrazine
Non-Small Cell Lung Carcinoma
Placebos
Gluconeogenesis
Survival
Etoposide
Pharmaceutical Preparations
Cisplatin
Quality of Life
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loprinzi, C. L., Goldberg, R. M., Su, J. Q., Mailliard, J. A., Kuross, S. A., Maksymiuk, A. W., ... Burch, P. A. (1994). Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. Journal of Clinical Oncology, 12(6), 1126-1129.

Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. / Loprinzi, Charles Lawrence; Goldberg, Richard M.; Su, John Q.; Mailliard, James A.; Kuross, Steven A.; Maksymiuk, Andrew W.; Kugler, John W.; Jett, James R.; Ghosh, Chirantan; Pfeifle, Delano M.; Wender, Donald B.; Burch, Patrick A.

In: Journal of Clinical Oncology, Vol. 12, No. 6, 06.1994, p. 1126-1129.

Research output: Contribution to journalArticle

Loprinzi, CL, Goldberg, RM, Su, JQ, Mailliard, JA, Kuross, SA, Maksymiuk, AW, Kugler, JW, Jett, JR, Ghosh, C, Pfeifle, DM, Wender, DB & Burch, PA 1994, 'Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer', Journal of Clinical Oncology, vol. 12, no. 6, pp. 1126-1129.
Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. Journal of Clinical Oncology. 1994 Jun;12(6):1126-1129.
Loprinzi, Charles Lawrence ; Goldberg, Richard M. ; Su, John Q. ; Mailliard, James A. ; Kuross, Steven A. ; Maksymiuk, Andrew W. ; Kugler, John W. ; Jett, James R. ; Ghosh, Chirantan ; Pfeifle, Delano M. ; Wender, Donald B. ; Burch, Patrick A. / Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 6. pp. 1126-1129.
@article{163457286c794dfda6de64d81fd1eaf3,
title = "Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer",
abstract = "Purpose: Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. Patients and Methods: Patients on this trial had newly diagnosed, unresectable non-small-cell lung cancer and were treated with cisplatin and etoposide. In addition, they were randomized to receive hydrazine sulfate or placebo in a double-blind manner. Results: A total of 243 patients were randomized. Response rates were similar in the two treatment arms. There were trends for worse time to progression and survival in the hydrazine sulfate arm. No significant differences were noted in the two study arms with regard to toxicity or quality of life (QL). Conclusion: This trial failed to demonstrate any benefit for patients who received hydrazine sulfate.",
author = "Loprinzi, {Charles Lawrence} and Goldberg, {Richard M.} and Su, {John Q.} and Mailliard, {James A.} and Kuross, {Steven A.} and Maksymiuk, {Andrew W.} and Kugler, {John W.} and Jett, {James R.} and Chirantan Ghosh and Pfeifle, {Delano M.} and Wender, {Donald B.} and Burch, {Patrick A.}",
year = "1994",
month = "6",
language = "English (US)",
volume = "12",
pages = "1126--1129",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer

AU - Loprinzi, Charles Lawrence

AU - Goldberg, Richard M.

AU - Su, John Q.

AU - Mailliard, James A.

AU - Kuross, Steven A.

AU - Maksymiuk, Andrew W.

AU - Kugler, John W.

AU - Jett, James R.

AU - Ghosh, Chirantan

AU - Pfeifle, Delano M.

AU - Wender, Donald B.

AU - Burch, Patrick A.

PY - 1994/6

Y1 - 1994/6

N2 - Purpose: Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. Patients and Methods: Patients on this trial had newly diagnosed, unresectable non-small-cell lung cancer and were treated with cisplatin and etoposide. In addition, they were randomized to receive hydrazine sulfate or placebo in a double-blind manner. Results: A total of 243 patients were randomized. Response rates were similar in the two treatment arms. There were trends for worse time to progression and survival in the hydrazine sulfate arm. No significant differences were noted in the two study arms with regard to toxicity or quality of life (QL). Conclusion: This trial failed to demonstrate any benefit for patients who received hydrazine sulfate.

AB - Purpose: Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. Patients and Methods: Patients on this trial had newly diagnosed, unresectable non-small-cell lung cancer and were treated with cisplatin and etoposide. In addition, they were randomized to receive hydrazine sulfate or placebo in a double-blind manner. Results: A total of 243 patients were randomized. Response rates were similar in the two treatment arms. There were trends for worse time to progression and survival in the hydrazine sulfate arm. No significant differences were noted in the two study arms with regard to toxicity or quality of life (QL). Conclusion: This trial failed to demonstrate any benefit for patients who received hydrazine sulfate.

UR - http://www.scopus.com/inward/record.url?scp=0028287946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028287946&partnerID=8YFLogxK

M3 - Article

C2 - 8201374

AN - SCOPUS:0028287946

VL - 12

SP - 1126

EP - 1129

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -